Randomized three arm phase III trial on induction and reinduction treatment with FOLFOX (5-fluorouracil, folinic acid and oxaliplatin regimen) or XELOX (capecitabine and oxaliplatin regimen) both with bevacizumab until progression or with or without maintenance treatment with bevacizumab alone for first-line treatment of patients with metastatic colorectal cancer

5-Fluorouracil (5-FU), Folinsäure, Capecitabin (Xeloda®), Bevacizumab (Avastin®)

Status: Studie beendet

Klinische Settings

Beteiligte

Identifier

Links

Kontakt